PEP
🔴 PepsiCo (PEP) is trading at 17 times earnings, with a dividend yield of nearly 4%, levels not seen historically.
📉 There is currently low investor appetite for consumer staples, creating a potential buying opportunity.
⚠️ Concerns about GLP-1 drugs and weight loss medications have negatively impacted the stock, but their effect is not yet significant.
@Artedeinvertir:
“Pepsi (PEP) has recently decreased and is at 17 times earnings, with dividend yields of almost 4%, which is historically unusual. There isn’t much appetite for investing in these categories right now, and there are fears about GLP-1 drugs and weight loss medications, but they are not having a noticeable effect.”
Watch the exact part of the video where Artedeinvertir talks about Pepsico here:
Watch the video on YouTube.
Read more articles by the world’s top 100 analysts on Pepsico (PEP) at the following link. PEP stock.
